中国科技核心期刊
CN:31-1600/Q
ISSN:1004-0374
“健康与疾病的免疫”国际学术研讨会通知      关于有网站冒充本刊网站的声明
《生命科学》 2010, 22(8): 772-777
松弛素在心血管疾病中的研究进展
高 照1,李法琦2*
(1海南省人民医院康复医疗中心,海口 570311;2 重庆医科大学附属第一医院老年病科,重庆 400016)
摘 要:松弛素是一类新近发现可作用于心血管的肽类激素,参与心血管系统的生理和病理过程。大量实验研究显示松弛素有扩血管、改善心血管重塑及调节炎症反应的心血管保护作用,也有利于改善高凝状态和胰岛素抵抗。松弛素作用广泛,可与松弛素受体或糖皮质激素受体结合,但其受体后的确切机制以及不同生理和病理状态对松弛素的调控还需进一步基础研究阐明。在从实验室到临床应用转化的初期临床试验中可观察到,人重组松弛素治疗急慢性心力衰竭安全性好,可改善症状、血流动力学指标及近期预后,为Ⅲ期临床试验奠定了基础,其临床应用前景令人期待。
关键词:松弛素;心血管系统;临床试验
 
Research advances of relaxin and its role in cardiovascular diseases
GAO Zhao1, LI Fa-qi2*
(Medical Rehabilitation Center, Hainan Provincial People抯 Hospital, Haikou 570311, China; 2 Department of Gerontology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China)

Abstract: It is recently found that relaxin (RLX), a peptide hormone, has an action on heart and vessels, involved in the physiologic and pathological processes of cardiovascular system. Accumulating studies have documented that RLX has cardiovascular protective effects on systematic vasodilation, cardiovascular remodeling and inflammatory reaction, and improves hypercoagulative state and insulin resistance as well. RLX exerts multiple effects, where the exact mechanisms behind the receptor-binding and modulation of RLX under different physiologic or pathologic conditions still need further elucidation. In translation of experimental findings to clinic therapy, the clinical trials on compensatory and acute heart failure in early stages suggest safe administration of recombinant human RLX, improvement of symptoms, hemodynamical indexes and short-term prognosis, which laid a good foundation for the phase Ⅲ clinical trial with expectation for positive findings.
Key words: relaxin; cardiovascular system; clinical trial


    

 

 
首页 | 刊物简介 | 编委会 | 投稿须知 | 广告业务 | 过刊浏览 | 联系我们
中国科学院上海生命科学信息中心《生命科学》编辑部
Copyright © 2012-2015 《生命科学》编辑部 All Rights Reserved.
沪ICP备05033115号-30
您是第2990236 位访问者,欢迎!